MedDataX Logo

Two WeChat Mini Program-based Interventions Reducing Sexual Risk Behaviors Among Heterosexual Male Factory Workers

NCT05811611 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2023-04-13

No results posted yet for this study

Summary

A non-blinded parallel group randomized controlled trial is conducted. Adult male full-time employees of factories in Shenzhen who have access to smartphone and WeChat are recruited by staff of the Longhua Center for Disease Control and Prevention (CDC).

After completing an online baseline questionnaire, participants will be randomized evenly to either the intervention group or the control group. Participants in the control group will have access to a WeChat Mini Program providing HIV and sexually transmitted prevention information during the project period. In addition to those received by the control group, the Mini Program will proactively ask participants in the intervention group some simple questions to assess presence of sexual risk behaviors at Month 0 and Month 1, and invite them to watch online health promotion video(s) tailored to their current sexual risk behaviors.

All participants will complete two online follow-up surveys six and twelve months after completion of the interventions.

Conditions

  • Behavior, Sex

Interventions

BEHAVIORAL

WeChat Mini Program plus tailored online health promotion videos

Participants have access to a WeChat Mini Program. Participants will also watch online health promotion videos tailored to their current sexual behaviors.

BEHAVIORAL

WeChat Mini Program Only

Participants only have access to a WeChat Mini Program.

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Zixin Wang, PhD · Chinese University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2023-04-30
Completion
2023-04-30

Countries

  • Hong Kong

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05811611 on ClinicalTrials.gov